DESCRIPTION (provided by applicant): It has been shown in various laboratories that the tissue plasminogen activator (tPA)/plasmin system is critical for excitotoxin-mediated seizures and neurodegeneration in the hippocampus. Upon excitotoxic challenge, tPA activates plasminogen to produce excess plasmin, which then degrades a critical component of the extracellular matrix (ECM), laminin. The loss of the neuron-matrix connection facilitates neuronal death as it does with other cell types.
We have found that tPA activity during ethanol treatment and EW is up-regulated in the mouse hippocampus and the amygdala, and that tPA-/- mice are protected from EW-induced seizures and neurodegeneration, as they are from these pathologies induced by excitotoxin injection. Therefore, the mechanism(s) of excitotoxinand EW-induced seizures and neurodegeneration have at least one molecule in common, tPA.
To understand better the mechanism of EW-induced seizures and neurodegeneration, we propose to systematically explore the role of tPA in these processes
National Institute on Alcohol Abuse and Alcoholism
CFDA Code
273
DUNS Number
071037113
UEI
LHGDNJMZ64Y1
Project Start Date
20-April-2005
Project End Date
31-March-2010
Budget Start Date
01-April-2006
Budget End Date
31-March-2007
Project Funding Information for 2006
Total Funding
$420,920
Direct Costs
$249,065
Indirect Costs
$171,855
Year
Funding IC
FY Total Cost by IC
2006
National Institute on Alcohol Abuse and Alcoholism
$420,920
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AA014630-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AA014630-02
Patents
No Patents information available for 5R01AA014630-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AA014630-02
Clinical Studies
No Clinical Studies information available for 5R01AA014630-02
News and More
Related News Releases
No news release information available for 5R01AA014630-02
History
No Historical information available for 5R01AA014630-02
Similar Projects
No Similar Projects information available for 5R01AA014630-02